SCHEMBL5714271

SCHEMBL5714271

O=C(Oc1ccc(CCOc2ccncc2)cc1)N1CCN(CCc2ccccn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.51
THRB P10828 4/20 0.50
ADORA3 P0DMS8 1/20 0.47
HTR2A P28223 1/20 0.47
HTR7 P34969 1/20 0.47
OPRM1 P35372 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
POLB P06746 2/20 0.47
HRH2 P25021 1/20 0.47
HRH1 P35367 1/20 0.47
LMNA P02545 1/20 0.47
SLC6A7 Q99884 1/20 0.45
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715097 0.94 HTR2A (0.52) TP53THRBADORA3HTR2AHTR7
SCHEMBL5714731 0.91 ALDH1A1 (0.53) THRBSLC6A7
SCHEMBL5714989 0.90 DRD2 (0.49) TP53THRBDRD3
SCHEMBL5713927 0.89 TP53 (0.52) TP53THRBADORA3HTR2AHTR7
SCHEMBL5714108 0.88 TP53 (0.48) TP53THRBADORA3HTR2AHTR7
SCHEMBL5714720 0.87 THRB (0.49) THRBADORA3HTR2AHTR7OPRM1
SCHEMBL5714755 0.86 THRB (0.50) THRBADORA3HTR2AHTR7OPRM1
SCHEMBL5714116 0.86 TP53 (0.59) TP53THRBLMNA
SCHEMBL5715718 0.85 THRB (0.49) THRBADORA3HTR2AHTR7OPRM1
SCHEMBL5714891 0.85 THRB (0.51) THRBADORA3HTR2AHTR7OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL TP53 2326/4885THRB 598/4885ADORA3 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.